Imagine waking up from prostate cancer surgery with a better chance of keeping your bladder control and sexual function. That is the promise of a technique called NeuroSAFE. It gives surgeons a real-time look at the tissue they remove during the operation. This quick check helps them make smarter choices about saving nerves while still removing all the cancer.
Prostate cancer is the most common cancer in men. Surgery to remove the prostate is a common treatment. The goal is to cure the cancer. But the surgery can harm the nerves and muscles that control urination and erections. Many men struggle with leakage or erectile dysfunction after the procedure. These side effects can be life changing. Men and their doctors often face a tough trade-off. Remove more tissue to be safe from cancer, or preserve more tissue to protect function.
This does not mean this treatment is available at every hospital yet.
The old way of thinking was to choose between cancer control and quality of life. Surgeons would often remove a wide margin of tissue to be sure they got all the cancer. This could mean cutting nerves that help with bladder control and erections. The new research suggests a different path. It shows that a careful, real-time check can help surgeons preserve more tissue without raising the cancer risk. This is the twist. It is not about guessing. It is about looking.
Think of the nerves around the prostate like a delicate electrical wiring system. These nerves control the bladder and sexual function. During standard surgery, the surgeon relies on their eyes and experience to decide what to save. It is like trying to fix a watch in the dark. NeuroSAFE turns on the lights. The surgeon removes a thin slice of tissue and freezes it. A pathologist looks at it under a microscope right away. This takes about 20 minutes. If the margin is clear, the surgeon knows it is safe to preserve more nerve tissue. If cancer cells are at the edge, the surgeon can remove a bit more. It is a safety net that guides the surgeon in the moment.
The review looked at 13 studies. These included two randomized trials and eleven observational studies. Together, they covered over 22,000 patients. The researchers compared men who had NeuroSAFE during robotic prostate surgery with men who had the standard approach. They followed the patients to see how their function recovered and whether the cancer came back. This is a large and thorough look at the evidence.
The results were clear. Men who had NeuroSAFE were twice as likely to recover erectile function compared to those who had standard surgery. They were also more likely to regain bladder control. The odds of having cancer cells at the edge of the removed tissue were lower too. This means the surgeons were more likely to remove all the cancer. Importantly, there was no difference in the rate of cancer recurrence over time. The technique did not compromise cancer control.
But there is a catch. The studies were not all perfect. Some were observational, which means they compared groups that were not randomly assigned. This can introduce bias. The researchers noted a serious risk of bias in many of the non-randomized studies. This means we cannot say for sure that NeuroSAFE causes these better outcomes. It might be that surgeons who use NeuroSAFE are also more skilled or more careful. The findings are promising, but they need confirmation from more large, randomized trials.
Experts in the field see NeuroSAFE as a practical tool. It is already used in some hospitals in Europe and the United States. The technique fits well with robotic surgery, which allows for very precise movements. The key is training. Surgeons need to learn how to handle the frozen tissue and interpret the pathologist’s report quickly. The review suggests that hospitals should consider adopting NeuroSAFE when they have the right team and resources.
For patients, this means it is worth asking your surgeon about nerve-sparing techniques. If your hospital offers NeuroSAFE, it could be a good option. It may improve your chances of keeping bladder control and sexual function after surgery. But it is not a guarantee. Every patient is different. The best approach depends on your cancer stage, your overall health, and the skill of your surgical team. Talk to your doctor about what is right for you.
The study has limits. Most of the data came from observational studies. The number of randomized trials was small. The patients were mostly from specialized centers. This means the results might not apply to all hospitals. Also, the follow-up time was not always long. We need more data over many years to see if the benefits last.
What happens next? More randomized trials are underway. Researchers are also looking at ways to make the frozen section process faster and cheaper. If the results hold up, NeuroSAFE could become a standard part of robotic prostate surgery. For now, it is a promising option that balances cancer control and quality of life.
